Clinical Insights in...non-alcoholic fatty liver disease and can cause a wide range of liver damage....
1
Sources: https://www.nature.com/articles/nrgastro.2017.109#global-perspectives www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts www.merckmanuals.com/professional/hepatic-and-biliary-disorders/approach-to-the-patient-with-liver-disease/nonalcoholic-steatohepatitis-nash www.aasld.org/sites/default/files/NAFLD%20Guidance%202018.pdf www.hopkinsmedicine.org/healthlibrary/conditions/liver_biliary_and_pancreatic_disorders/nonalcoholic_fatty_liver_disease_134,178 Definition: (NAFLD) is non-alcoholic fatty liver disease and can cause a wide range of liver damage. There are 2 types of NAFLD, NAFL or simple fatty liver, and nonalcoholic steatohepatitis (NASH) which has a high risk of progression and can lead to cirrhosis Diagnosis: Fat in the liver can be seen on imaging, however biopsy is still required to diagnose NASH. Non-invasive technology is evolving as guidelines evolve on how to diagnose this important liver injury. Normal Liver Non-Alcoholic Fatty Liver Disease (NAFLD) Non-Alcoholic SteatoHepatitis (NASH) Clinical Insights in NAFLD and NASH for 2018 From Clinical Liver Disease Prevalence: The prevalence of NAFLD/NASH is now 24% of the global population with an estimated 64 MM (USA) and 52 MM(Europe) impacted. Treatment aspects NASH and NAFLD have been treated with both drugs and modification of lifestyle factors. Treatment: Life style modification remains the cornerstone of therapy but is hard to maintain. Weight loss is key to improvement with a 3–5% reduction of body weight leading to a decrease in fat in the liver. Many therapeutics have been disappointing, but a new class of new drugs are in the pipeline. Current guidelines recommend Vitamin E and Pioglitazone for specific populations. Go to bit.ly/NASHin2018 to read the free Special issue on Clinical Insights in NAFLD and NASH for 2018.
Transcript of Clinical Insights in...non-alcoholic fatty liver disease and can cause a wide range of liver damage....
Sources: https://www.nature.com/articles/nrgastro.2017.109#global-perspectiveswww.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts www.merckmanuals.com/professional/hepatic-and-biliary-disorders/approach-to-the-patient-with-liver-disease/nonalcoholic-steatohepatitis-nash www.aasld.org/sites/default/files/NAFLD%20Guidance%202018.pdf www.hopkinsmedicine.org/healthlibrary/conditions/liver_biliary_and_pancreatic_disorders/nonalcoholic_fatty_liver_disease_134,178
Definition: (NAFLD) is non-alcoholic fatty liver disease and can cause a wide range of liver damage. There are 2 types of NAFLD, NAFL or simple fatty liver, and nonalcoholic steatohepatitis (NASH) which has a high risk of progression and can lead to cirrhosis
Diagnosis: Fat in the liver can be seen on imaging, however biopsy is still required to diagnose NASH. Non-invasive technology is evolving as guidelines evolve on how to diagnose this important liver injury.
Normal Liver Non-Alcoholic Fatty Liver Disease
(NAFLD)
Non-Alcoholic SteatoHepatitis
(NASH)
Clinical Insights in NAFLD and NASH for 2018 From Clinical Liver Disease
Prevalence: The prevalence of NAFLD/NASH is now 24% of the global population with an estimated 64 MM (USA) and 52 MM(Europe) impacted.
Treatment aspects NASH and NAFLD have been treated with both drugs and modification of lifestyle factors.
Treatment: Life style modification remains thecornerstone of therapy but is hard to maintain. Weightloss is key to improvement with a 3–5% reduction of body weight leading to a decrease in fat in the liver.
Many therapeutics have been disappointing, but a new class of new drugs are in the pipeline. Current guidelines recommend Vitamin E and Pioglitazone for specific populations.
Go to bit.ly/NASHin2018 to read the free Special issue on Clinical Insights in NAFLD and NASH for 2018.
